Clinical factors and vascular endothelial growth factor as determinants of disease progression in Indian patients with amyotrophic lateral sclerosis

References

• Xu L, Liu T, Liu L, Yao X, Chen L, Fan D, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020;267:944–53.
   PubMed Web of Science ®Google Scholar
• Goutman SA, Hardiman O, Al-Chalabi A, Chió A, Savelieff MG, Kiernan MC, et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21:480–93.
   PubMed Web of Science ®Google Scholar
• Wang MD, Little J, Gomes J, Cashman NR, Krewski D. Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis. Neurotoxicology 2017;61:101–30.
   PubMed Web of Science ®Google Scholar
• Creemers H, Grupstra H, Nollet F, van den Berg LH, Beelen A. Prognostic factors for the course of functional status of patients with ALS: a systematic review. J Neurol. 2015;62:1407–23.
   Google Scholar
• Iłzecka J. Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis. Clin Neurol Neurosurg. 2004;106:289–93.
   PubMed Web of Science ®Google Scholar
• Khosla R, Rain M, Chawathey S, Modgil S, Tyagi R, Thakur K, et al. Identifying putative cerebrospinal fluid biomarkers of amyotrophic lateral sclerosis in a north Indian population. Muscle Nerve. 2020;62:528–33.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Tilkin P, Mercer KJ, Terryn J, D'Hondt A, Herne N, et al. Intracerebroventricular delivery of vascular endothelial growth factor in patients with amyotrophic lateral sclerosis, a phase I study. Brain Commun. 2020; S2:fcaa160.
   PubMedGoogle Scholar
• Devos D, Moreau C, Lassalle P, Perez T, De Seze J, Brunaud-Danel V, et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology 2004;62:2127–9.
   PubMed Web of Science ®Google Scholar
• Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Destée A, et al. Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J Neurol Neurosurg Psychiatry. 2006;77:255–7.
   PubMed Web of Science ®Google Scholar
• Vijayalakshmi K, Ostwal P, Sumitha R, Shruthi S, Varghese AM, Mishra P, et al. Role of VEGF and VEGFR2 receptor in reversal of ALS-CSF induced degeneration of NSC-34 motor neuron cell line. Mol Neurobiol. 2015;51:995–1007.
   PubMed Web of Science ®Google Scholar
• Anand A, Gupta PK, Sharma NK, Prabhakar S. Soluble VEGFR1 (sVEGFR1) as a novel marker of amyotrophic lateral sclerosis (ALS) in the North Indian ALS patients. Eur J Neurol. 2012;19:788–92.
   PubMed Web of Science ®Google Scholar
• Shantanu S, Vijayalakshmi K, Shruthi S, Sagar BKC, Sathyaprabha TN, Nalini A, et al. VEGF alleviates ALS-CSF induced cytoplasmic accumulations of TDP-43 and FUS/TLS in NSC-34 cells. J Chem Neuroanat. 2017;81:48–52.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhou S, Cai H, Gong Z, Zang D. VEGF levels in CSF and serum in mild ALS patients. J Neurol Sci. 2014;346:216–20.
   PubMed Web of Science ®Google Scholar
• Bogaert E, Van Damme P, Poesen K, Dhondt J, Hersmus N, Kiraly D, et al. VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. Neurobiol Aging. 2010;31:2185–91.
   PubMed Web of Science ®Google Scholar
• Gupta PK, Prabhakar S, Abburi C, Sharma NK, Anand A. Vascular endothelial growth factor-A and chemokine ligand (CCL2) genes are upregulated in peripheral blood mononuclear cells in Indian amyotrophic lateral sclerosis patients. J Neuroinflammation. 2011;8:114.
   PubMed Web of Science ®Google Scholar
• Agosta F, Al-Chalabi A, Filippi M, Hardiman O, Kaji R, Meininger V, et al. The El Escorial criteria: strengths and weaknesses. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:1–7.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (Phase III). J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Guo J, Yang X, Gao L, Zang D. Evaluating the levels of CSF and serum factors in ALS. Brain Behav. 2017;7:e00637.
   PubMed Web of Science ®Google Scholar
• Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006;66:265–7.
   PubMed Web of Science ®Google Scholar
• Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist Med. 1996;15:361–87.
   PubMed Web of Science ®Google Scholar
• Goyal NA, Berry JD, Windebank A, Staff NP, Maragakis NJ, van den Berg LH, et al. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve. 2020;62:156–66.
   PubMed Web of Science ®Google Scholar
• Nalini A, Thennarasu K, Gourie-Devi M, Shenoy S, Kulshreshtha D. Clinical characteristics and survival pattern of 1,153 patients with amyotrophic lateral sclerosis: experience over 30 years from India. J Neurol Sci. 2008;272:60–70.
   PubMed Web of Science ®Google Scholar
• Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.
   PubMed Web of Science ®Google Scholar
• Rosenbohm A, Peter RS, Erhardt S, Lulé D, Rothenbacher D, Ludolph AC, et al. Epidemiology of amyotrophic lateral sclerosis in Southern Germany. J Neurol. 2017;264:749–57.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Atsuta N, Nakamura R, Hirakawa A, Watanabe H, Ito M, et al. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:230–6.
   PubMed Web of Science ®Google Scholar
• Manera U, Calvo A, Daviddi M, Canosa A, Vasta R, Torrieri MC, et al. Regional spreading of symptoms at diagnosis as a prognostic marker in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2020;91:291–7.
   PubMed Web of Science ®Google Scholar
• Manera U, D'Ovidio F, Cabras S, Torrieri MC, Canosa A, Vasta R, et al. Amyotrophic lateral sclerosis regional progression intervals change according to time of involvement of different body regions. Eur J Neurol. 2023;30:872–80.
   PubMed Web of Science ®Google Scholar
• Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423–33.
   PubMed Web of Science ®Google Scholar
• Su WM, Cheng YF, Jiang Z, Duan QQ, Yang TM, Shang HF, et al. Predictors of survival in patients with amyotrophic lateral sclerosis: a large meta-analysis. EBioMedicine 2021;74:103732.
   PubMed Web of Science ®Google Scholar
• Kjældgaard AL, Pilely K, Olsen KS, Jessen AH, Lauritsen AØ, Pedersen SW, et al. Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study. BMC Neurol. 2021;21:164.
   PubMed Web of Science ®Google Scholar
• Elamin M, Bede P, Montuschi A, Pender N, Chio A, Hardiman O. Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. J Neurol. 2015;262:1447–54.
   PubMed Web of Science ®Google Scholar
• Thakur K, Tiwari A, Sharma K, Modgil S, Khosla R, Anand A. Angiogenesis-centered molecular cross-talk in amyotrophic lateral sclerosis survival: mechanistic insights. Crit Rev Eukaryot Gene Expr. 2020;30:137–51.
   PubMed Web of Science ®Google Scholar
• Calvo PM, Hernández RG, de la Cruz RR, Pastor AM. Role of vascular endothelial growth factor as a critical neurotrophic factor for the survival and physiology of motoneurons. Neural Regen Res. 2023;18:1691–6.
   PubMed Web of Science ®Google Scholar
• Chen X, Hu Y, Cao Z, Liu Q, Cheng Y. Cerebrospinal fluid inflammatory cytokine aberrations in alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Front Immunol. 2018;9:2122.
   PubMed Web of Science ®Google Scholar
• Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870–81.
   PubMed Web of Science ®Google Scholar
• Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577–89.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Abbruzzese G, Arata L, Cocito L, Vische M. Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. J Neurol. 1984;231:75–8.
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang F, Wang H, Cui F, Li M, Sun B, et al. The increase in CSF total protein and immunoglobulins in Chinese patients with sporadic amyotrophic lateral sclerosis: a retrospective study. J Neurol Sci. 2020;414:116840.
   PubMed Web of Science ®Google Scholar